Drug intelligence / Profile preview

BITULIV

Development stage: Unknown
Lead developer: Amvia Biotech
Administration: Oral

Overview

BITULIV is an Ayurvedic hepatoprotective preparation developed by Amvia Biotech. It is formulated for liver support and general hepatoprotection, available in both oral suspension (syrup) and capsule forms. As a traditional Ayurvedic medicine, it is designed to maintain liver health and function, although the specific herbal constituents and their individual mechanisms of action are not detailed in the manufacturer's pipeline. It is typically used as a supportive therapy for various liver-related conditions to protect hepatic cells from damage.

Brand names: BITULIV
Other names: BITULIV SuspensionBITULIV Capsules

Targets

AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)MMP12 (Macrophage Metalloelastase)KEAP1 (Kelch-like ECH-associated protein 1)VEGFA (Vascular endothelial growth factor A)IL-6 (Interleukin 6)

Beyond the preview

Go deeper on BITULIV.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BITULIV.

Explore the full profile